Materialise (NasdaqGS:MTLS) opened 2026 with Q1 revenue of €66.3 million and basic EPS of €0.03. This helps set the tone for how the year is starting to shape up after a busy 2025. The company has seen quarterly revenue move between €64.8 million and €70.2 million over the past year, while basic EPS ranged from a small loss of €0.01 in Q1 2025 to €0.11 in Q4 2025. This gives investors a clearer view of how profits track against a relatively steady top line. With trailing twelve month net income at €10.1 million and net profit margins nudging higher, the latest print keeps the focus on how consistently Materialise can convert revenue into earnings.

See our full analysis for Materialise.

With the latest figures set, the next step is to see how these numbers line up against the widely held narratives about Materialise, highlighting where the story is confirmed and where it might need a rethink.

See what the community is saying about Materialise

Margins Edge Up To 3.8%

• Over the last 12 months, Materialise converted €267.5 million of revenue into €10.1 million of net income, which works out to a 3.8% net margin compared with 3.5% a year earlier.
• Consensus narrative focuses on higher value medical and software activity as a driver for better margins, and the recent figures partly back that up while also showing some friction:
  • Multi year earnings growth of about 15.1% per year and trailing 12 month net income of €10.1 million are consistent with a business that has been improving profit generation, even though one year earnings growth of 8.2% sits below that longer term pace.
  • At the same time, the consensus view highlights cost control and portfolio streamlining, and the gradual net margin lift from 3.5% to 3.8% supports that claim without yet pointing to a major step change.

Earnings Growth Outpaces Revenue

• Analysts in the dataset expect earnings to grow about 29.8% per year, compared with forecast revenue growth of around 7.6% per year and trailing 12 month revenue of €267.5 million.
• Bullish arguments about higher margin growth areas are reflected in the data, although the growth mix shows both strengths and constraints:
  • Bulls point to multi year earnings growth of roughly 15.1% per year and a forecast step up to 29.8% per year, which lines up with the idea that expanding personalized healthcare and cloud software could lift profitability faster than revenue.
  • However, expected revenue growth of 7.6% per year compared with the wider US market outlook of 11.4% means the bullish view is leaning more on margin improvement than on rapid top line expansion.

On these numbers, the bullish case leans heavily on how efficiently future growth converts into profit rather than on sheer sales volume, so it can be useful to see how those assumptions are laid out in detail before deciding how much weight to put on them 🐂 Materialise Bull Case.

Mixed Valuation Signals At €5.44

• With the share price at $5.44, the stock sits below both a DCF fair value of about $8.16 and a single allowed analyst price target of $8.77, while trading on a P/E of 26.9x versus a 14.2x peer average and 29.3x for the broader US Software group.
• Bears often focus on valuation pressure, and the current mix of metrics gives that view some support but not a clear verdict:
  • The higher P/E versus peers at 26.9x compared with 14.2x fits the cautious view that the stock is priced above closer comparables, even with revenue growth forecasts of 7.6% per year that sit below the 11.4% market benchmark.
  • On the other hand, trading around 33.4% below the stated DCF fair value of $8.16 and below the $8.77 analyst target suggests bears also have to contend with valuation models that point to a gap between price and intrinsic value.

For anyone weighing that caution against the current discount to intrinsic value estimates, it helps to see exactly how the more skeptical arguments about growth, margins, and multiples are built up from the numbers 🐻 Materialise Bear Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Materialise on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If the mix of bullish and bearish points still feels finely balanced, it helps to move quickly and test the data against your own thesis. Start by reviewing the 4 key rewards.

See What Else Is Out There

Materialise combines relatively modest forecast revenue growth of 7.6% per year with a 26.9x P/E that sits above peers, so some investors may question paying up for slower expansion.

If you want stocks where pricing looks less demanding relative to quality and outlook, check out the 50 high quality undervalued stocks to compare alternatives quickly.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.